论文部分内容阅读
本文从血小板在正常和疾病中的作用与理解血小板的功能出发 ,对研制中的抗血小板新药血小板GPⅡb/Ⅲa拮抗剂作了介绍。该类药物目前是与血小板激动剂无关的最强的血小板聚集特异性拮抗剂 ,已用于急性心肌缺血综合征 ,并作为标准抗血小板治疗的辅助药。临床试验表明 ,虽然GPⅡb/Ⅲa抑制剂的安全与疗效比、优化给药时间及出血等问题还有待解决 ,但其疗效显著 ,是有发展前景的新一代抗血栓药
This article from the platelet in the normal and disease function and understanding of the function of platelets, the development of antiplatelet drugs platelet GP Ⅱ b / Ⅲ a antagonists are introduced. These drugs are currently the strongest platelet aggregation-specific antagonists unrelated to platelet agonists and have been used as adjunctive to standard antiplatelet therapy in patients with acute myocardial ischemia syndrome. Clinical trials have shown that although the safety and efficacy of GP Ⅱ b / Ⅲ a inhibitors, optimization of drug delivery time and bleeding and other issues remain to be resolved, but its efficacy is significant, is a promising new generation of anti-thrombotic drugs